Abstract
CYP2D6 polymorphism is associated with variability in drug response, endogenous metabolism (that is, serotonin), personality, neurocognition and psychopathology. The relationship between CYP2D6 genetic polymorphism and the risk of eating disorders (ED) was analyzed in 267 patients with ED and in 285 controls. A difference in the CYP2D6 active allele distribution was found between these groups. Women carrying more than two active genes (ultrarapid metabolizers) (7.5 vs 4.6%) or two (67 vs 58.9%) active genes were more frequent among patients with ED, whereas those with one (20.6 vs 30.2%) or zero active genes (4.9 vs 6.3%) were more frequent among controls (P<0.05). Although further research is needed, present findings suggest an association between CYP2D6 and ED. CYP2D6 allele distribution in patients with ED seems related to increased enzyme activity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Dorado P, Cáceres M, Pozo-Guisado E, Wong ML, Licinio J, Llerena A . Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use. Biotechniques 2005; 39: 571–574.
LLerena A, Dorado P, Berecz R, González AP, Peñas-LLedó EM . Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. Eur J Clin Pharmacol 2004; 59: 869–873.
Shapiro JR, Berkman ND, Brownley KA, Sedway JA, Lohr KN, Bulik CM . Bulimia nervosa treatment: a systematic review of randomized controlled trials. Int J Eat Disord 2007; 40: 321–336.
LLerena A, Dorado P, Peñas-Lledó EM . Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity. Pharmacogenomics 2009; 10: 17–28.
Yu AM, Idle JR, Byrd LG, Krausz KW, Küpfer A, Gonzalez FJ . Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 2003; 13: 173–181.
Kirchheiner J, Henckel HB, Franke L, Meineke I, Tzvetkov M, Uebelhack R et al. Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets. Pharmacogenet Genomics 2005; 15: 579–587.
Ozdemir V, Bertilsson L, Miura J, Carpenter E, Reist C, Harper P et al. CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited. Pharmacogenet Genomics 2007; 17: 339–347.
Miksys SL, Tyndale RF . Drug-metabolizing cytochrome P450s in the brain. J Psychiatry Neurosci 2002; 27: 406–415.
LLerena A, Edman G, Cobaleda J, Benítez J, Schalling D, Bertilsson L . Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr Scand 1993; 87: 23–28.
González I, Peñas-Lledó EM, Pérez B, Dorado P, Alvarez M, LLerena A . Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers. Pharmacogenomics 2008; 9: 833–840.
Peñas-LLedó EM, Dorado P, Pacheco R, González I, LLerena A . Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers. Pharmacogenomics 2009; 10: 1111–1120.
Peñas-Lledó EM, Dorado P, LLerena A . Pharmacogenomics and personality: role of CYP2D6 and implication for psychopathology. In: Schwab M, Kaschka W, Spina E (eds). Pharmacogenomics in Psychiatry. Advances in Biological Psychiatry. Vol. 2. Karger Publishers: Basel, 2010, pp 30–45.
Zackrisson AL, Lindblom B, Ahlner J . High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases. Clin Pharmacol Ther 2010; 88: 354–359. (Published online 11 November 2009).
Kawanishi C, Lundgren S, Agren H, Bertilsson L . Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol 2004; 59: 803–807.
Josefsson A, Sydsjö G, Berg G, Dahl ML, Wadelius M, Nordin C . CYP2D6 genotypes and depressive symptoms during late pregnancy and postpartum. Nord J Psychiatry 2004; 58: 61–64.
Fernandez-Aranda F, Pinheiro AP, Tozzi F, Thornton LM, Fichter MM, Halmi KA et al. Symptom profile of major depressive disorder in females with eating disorders. Aust N Z J Psychiatry 2007; 41: 24–31.
Peñas-Lledó E, Fernández-Aranda F, Jiménez-Murcia S, Granero R, Penelo E, Soto A et al. Subtyping eating disordered patients along drive for thinness and depression. Behav Res Ther 2009; 47: 513–519.
Ribasés M, Fernández-Aranda F, Gratacòs M, Mercader JM, Casasnovas C, Núñez A et al. Contribution of the serotoninergic system to anxious and depressive traits that may be partially responsible for the phenotypical variability of bulimia nervosa. J Psychiatr Res 2008; 42: 50–57.
LLerena A, Dorado P, Peñas-Lledó EM, Cáceres MC, De la Rubia A . Low frequency of CYP2D6 poor metabolizers among schizophrenia patients. Pharmacogenomics J 2007; 7: 408–410.
Bacaltchuk J, Hay P . Antidepressants versus placebo for people with bulimia nervosa. Cochrane Database Syst Rev 2003. Issue no 4. Article no. CD003391.
Acknowledgements
This study was partially supported by grants from Instituto de Salud Carlos III (ISCIII)-FIS and European Union-FEDER PI081714 and CP06/00030 (Pedro Dorado). CIBER is an initiative of ISCIII (Spain). The study was coordinated within the network Red Iberoamericana de Farmacogenética y Farmacogenómica (CYTED206RT0290 www.ribef.org). The collaboration of Beatriz Grillo and Inés López in the genetic analysis and of Jesús Cobaleda in the evaluation of primary health-care attendants is gratefully acknowledged.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Peñas-LLedó, E., Dorado, P., Agüera, Z. et al. CYP2D6 polymorphism in patients with eating disorders. Pharmacogenomics J 12, 173–175 (2012). https://doi.org/10.1038/tpj.2010.78
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/tpj.2010.78
Keywords
This article is cited by
-
Human CYP2D6 Is Functional in Brain In Vivo: Evidence from Humanized CYP2D6 Transgenic Mice
Molecular Neurobiology (2020)
-
Human CYP2D6 in the Brain Is Protective Against Harmine-Induced Neurotoxicity: Evidence from Humanized CYP2D6 Transgenic Mice
Molecular Neurobiology (2020)
-
Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder
The Pharmacogenomics Journal (2014)
-
Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function
Molecular Psychiatry (2013)